

1 July 2026

ASX RELEASE

ANNUAL GENERAL MEETING TO BE HELD FRIDAY 28 AUGUST 2026

Melbourne, Australia 1 July 2026: Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company"), advises that its Annual General Meeting in respect of its financial year ended 31 March 2026 is to be held on Friday 28 August 2026.

Details of the meeting venue and other meeting arrangements will be confirmed at a later date.

In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by the Company not later than Friday 10 July 2026.

This ASX announcement was approved and authorised for release by the Company Secretary.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 411 235 692

U.S. Contact:

Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

U.S. Media:

media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the **ACCENT** trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone, and a mOS of 11.1 months has been reported. A second trial – AMPLICITY – is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com

Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com